Biotage Announces Research Collaboration with University of Copenhagen for Peptide Synthesis
Global demand from research scientists for synthetic peptides continues to grow at a double digit rate. Their needs are for increasingly longer and more complex peptides to study protein interactions, produce peptide antibodies, and understand complex disease states. As the number and complexity of peptides increase, the scientists and researchers need new tools that offer higher productivity and increased performance.
Biotage recently entered into collaboration with the German instrument company MultiSynTech GmbH (privately owned by Dr. Udo Treffer) and Professor Jensen to develop the Biotage Syro Wave automated peptide synthesizer introduced earlier this year. The instrument combines the proven technologies behind Biotage's Initiator microwave instrument with the wellestablished Syro line of robotic peptide synthesizers from MultiSynTech.
Professor Jensen says "The Syro Wave is the first valvefree peptide synthesizer with integrated microwave heating. It holds great promise for the synthesis of both long peptides and even small proteins."
For more information on the Biotage Syro Wave, please email email@example.com or visit www.biotage.com
About Biotage AB
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. The customers include the world's top pharma and biotech companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, and has offices in the United States, United Kingdom and Japan. Biotage has 253 employees and had sales of SEK 394,1m in 2009. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange.